EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma

James William Smithy, Allison Betof, Sebastian Klobuch, Troels Holz Borch, Hannah L Kalvin, Nitzan Hasson, Shirly Grynberg, Rodabe Amaria, Juliane A Czapla, Megan D Schollenberger, Andrew J S Furness, Jessica C Hassel und 16 weitere

Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e015360

DOI: 10.1136/jitc-2026-015360 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.06.2026. Verfasst von James William Smithy und 27 weiteren Autor:innen. Beteiligte Einrichtung: Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA smithyj@mskcc.org. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Lymphocytes, Tumor-Infiltrating, Melanoma. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Marilyn and Michael Glosserman Foundation for Melanoma and Basal Cell Carcinoma Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Treatment strategies for patients with advanced melanoma resistant to adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) remain undefined. The efficacy of immune checkpoint inhibitors (ICIs) after TIL has not been previously described. Patients and methods Patients with unresectable melanoma who received ICI therapy both before and after TIL treatment were retrospectively identified at 14 international centers. Safety was evaluated among all patients that received one dose of ICI therapy after TIL. Objective response rates (ORR) were determined based on investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 responses based on radiology reports. Kaplan-Meier methodology was used to estimate overall survival (OS) and melanoma-specific survival.

Results

Among 133 patients assessed for response to ICI therapy after progression on TIL therapy, the ORR was 11% (n=14; 95% CI 5.9% to 17%), including 3 complete responses (2.3%) and 11 partial responses (8.3%). Among patients treated with a programmed death-1 inhibitor prior to TIL (n=121), the ORR was 8.3% (95% CI 4.0% to 15%). At a median follow-up among survivors of 21 months, median OS from post-TIL ICI was 8.8 months (95% CI 6.5 to 12 months). Among 14 patients with response to post-TIL ICI, 13 received an ICI they had not previously received. In the safety cohort (n=138), post-TIL ICI therapy-related toxicity occurred in 31 patients(22%), among which 7 patients (5.1%) experienced recurrence of an adverse event experienced with prior ICI treatment.

Conclusion

Efficacy with ICI after TIL was limited, with no evidence of synergistic toxicity. As TIL therapy becomes more widely available, these data highlight the need for novel therapies in this setting and support the inclusion of this population in future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMelanomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

Adoptive cell therapy - ACTImmune Checkpoint InhibitorSkin Cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA smithyj@mskcc.org.
  • Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
  • Stanford University School of Medicine, Stanford, California, USA.
  • Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Oncology, National Center for Cancer Immunotherapy, Herlev, Denmark.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Marilyn and Michael Glosserman Foundation for Melanoma and Basal Cell Carcinoma Research

Zitieren

APA

Smithy, J. W., Betof, A., Klobuch, S., Borch, T. H., Kalvin, H. L., Hasson, N., Grynberg, S., Amaria, R., Czapla, J. A., Schollenberger, M. D., Furness, A. J. S., Hassel, J. C., Wermke, M., Pedersen, S., Svane, I. M., Ocejo, A., Buchbinder, E., Johnson, D. B., Postow, M., …, & Shoushtari, A. N. (2026). Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma. Journal for ImmunoTherapy of Cancer, 14(6), e015360. https://doi.org/10.1136/jitc-2026-015360

Vancouver

Smithy JW, Betof A, Klobuch S, Borch TH, Kalvin HL, Hasson N, et al. Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma. Journal for ImmunoTherapy of Cancer. 2026;14(6):e015360. doi:10.1136/jitc-2026-015360

BibTeX
@article{Smithy2026,
  author = {Smithy, James William and Betof, Allison and Klobuch, Sebastian and Borch, Troels Holz and Kalvin, Hannah L and Hasson, Nitzan and Grynberg, Shirly and Amaria, Rodabe and Czapla, Juliane A and Schollenberger, Megan D and Furness, Andrew J S and Hassel, Jessica C and Wermke, Martin and Pedersen, Sidsel and Svane, Inge Marie and Ocejo, Antonio and Buchbinder, Elizabeth and Johnson, Douglas B and Postow, Michael and Los, Cristy and Lutzky, Jose and Lipson, Evan J and Sullivan, Ryan J and Kluger, Harriet M and Panageas, Katherine S and Donia, Marco and Haanen, John B A G and Shoushtari, Alexander Noor},
  title = {Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {e015360},
  doi = {10.1136/jitc-2026-015360}
}
Kostenlos starten →